Nanosuspension: A Novel Approach for The Treatment of Hyperlipidaemia

Hyperlipidaemia is a condition characterized by increased levels of lipids in the bloodstream, which can lead to cardiovascular diseases such as stroke. The medications used to treat hyperlipidemia include statins, fibrates, and cholesterol absorption inhibitors, all of which have low water solubility, dissolution, and bioavailability. To address the issue of poor aqueous solubility, these BCS class II drugs often undergo nanosuspension formulation. Nanosuspensions, which are colloidal dispersions of nanosized drug particles, present a promising method for enhancing the pharmacokinetic characteristics of poorly water-soluble drugs. By reducing particle size to between 100 and 600 nm or converting the crystalline form of the drug into an amorphous form, nanosuspensions exhibit a high dissolution rate. During the preparation of nanosuspensions, stabilizers play a crucial role in reducing particle size and preventing the aggregation of drug particles.